On November 26, 2025 Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs targeting oncological and inflammatory diseases, reported that its CEO, Motti Farbstein will present at NobleCon21—Noble Capital Markets’ Twenty First Annual Emerging Growth Equity Conference—at Florida Atlantic University, Executive Education Complex, in Boca Raton, Floria—on Wednesday, December 3rd, 2025 at 12:30 PM ET. Mr. Farbstein will also conduct 1×1 meetings with investors.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Mr. Farbstein will present the latest developments in Can-Fite’s advanced stage drug development pipeline including the following trials:

Phase III liver cancer
Phase IIa pancreatic cancer
Phase III psoriasis
Phase IIb MASH
Upcoming Phase II in Lowe Syndrome
Can-Fite has numerous out-licensing and global distribution agreements in place worth up to $130 million for pharma indications, with an additional up to $325 million for veterinary indications.

A high-definition video webcast of the presentation will be available the following day on Can-Fite’s website www.canfite.com, and as part of a complete catalog of presentations available at Noble Capital Markets’ Conference website at www.nobleconference.com and on Channelchek www.channelchek.com, the investor portal created by Noble. The webcast will be archived on Can-Fite’s website, the NobleCon website, and on Channelchek.com for 90 days following the event.

(Press release, Can-Fite BioPharma, NOV 26, 2025, View Source [SID1234660979])

On November 26, 2025 SK Biopharmaceuticals, CO., Ltd., a biotech company specializing in research, development, and commercialization of treatments for central nervous system (CNS) disorders and oncology, reported a license agreement with the Wisconsin Alumni Research Foundation (WARF) to acquire the exclusive worldwide rights for research and development (R&D), manufacturing, and commercialization of WARF’s "WT-7695," a preclinical-stage radiopharmaceutical therapy candidate developed in collaboration with the University of Wisconsin-Madison.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

This agreement represents SK Biopharmaceuticals’ second in-licensed asset in the radiopharmaceutical therapy field, following its first asset "SKL35501 (formerly FL-091)" in 2024. Since then, SK Biopharmaceuticals has continued to strengthen its foundation in the radiopharmaceutical field through supply agreements with TerraPower, a U.S. nuclear innovation company, and PanTera, a Belgian radioisotope producer, securing Actinium-225 (225Ac), and through multiple research collaboration agreements to broaden its expertise and capabilities across the full radiopharmaceutical value chain.

WT-7695 is a small-molecule radiopharmaceutical candidate in preclinical stage designed to target carbonic anhydrase IX (CA9), a transmembrane protein that plays a critical role in cancer cell growth and metastasis under hypoxic conditions. CA9 is highly expressed in clear cell renal cell carcinoma (ccRCC)[1] and other solid tumors such as pancreatic and colorectal cancers — making it a validated and selective target for radiopharmaceutical therapy development. Preclinical studies have shown promising efficacy, suggesting that WT-7695 has the potential to become a best-in-class radiopharmaceutical candidate.

Through this license agreement, SK Biopharmaceuticals continues to pursue a balanced growth strategy, strengthening internal capabilities while expanding strategic partnerships to advance R&D in radiopharmaceutical therapy. The company aims to build a robust and comprehensive radiopharmaceutical value chain, encompassing drug discovery, radioisotope sourcing, preclinical and clinical development.

"This agreement underscores the promise of CA9 as a target in advancing cancer treatment for patients around the world," said Erik Iverson, CEO of WARF. "We’re deeply proud of the collaboration between our WARF Therapeutics team and the University of Wisconsin-Madison researchers, whose work paved the way for this partnership with SK Biopharmaceuticals. Together, we’re committed to accelerating the development of this promising therapy and bringing it closer to the patients who need it."

"By securing this promising candidate with demonstrated preclinical efficacy, SK Biopharmaceuticals will further diversify its radiopharmaceutical therapy portfolio and reinforce its R&D capabilities through global collaboration," said Donghoon Lee, CEO of SK Biopharmaceuticals. "We will continue to expand our pipeline based on validated targets, strengthen our expertise across the integrated radiopharmaceutical value chain, and accelerate the development of next-generation cancer treatments to deliver meaningful solutions for patients with high unmet medical needs worldwide."

(Press release, SK biopharmaceuticals, NOV 26, 2025, View Source [SID1234660980])

On November 26, 2025 Whitehawk Therapeutics, Inc. (Nasdaq: WHWK), an oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver improved antibody drug conjugate (ADC) cancer treatments, reported that Dave Lennon, PhD, President and CEO, will participate in a fireside discussion at the Piper Sandler 37th Annual Healthcare Conference in New York City, NY on December 3, 2025, at 12:30 PM ET.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live webcast of the fireside chat can be accessed by visiting the Whitehawk Therapeutics IR website and will be available for replay for approximately 30 days following the event.

(Press release, Whitehawk Therapeutics, NOV 26, 2025, View Source [SID1234660981])

On November 26, 2025 Curasight A/S ("Curasight" or "the Company" (CPH: CURAS), a clinical stage radiopharmaceuticals company, reported its phase 1 trial investigating uTREAT in aggressive brain cancer is now open for patient enrollment.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Regulatory approval from the Health Authority and ethical committee approval has been obtained, and all practical and logistical preparations at the trial site have been completed. Dosing the first patient is expected in the coming weeks.

The phase 1 trial is part of Curasight’s theranostic strategy developing more gentle and targeted diagnosis and treatment of certain types of cancer.

"It is a very exciting stage in the development of uTREAT, that we are now ready to enroll patients and progress the development of uTREAT as a potential more targeted therapeutic solution for patients with aggressive brain cancer. There is a high unmet medical need for new treatments for brain cancer, and we look forward to enrolling the first patient very soon," said Curasight’s CEO, Ulrich Krasilnikoff.

About the Phase 1 trial with uTREAT in brain cancer

The trial aims to investigate Curasight’s uTREAT as a new type of targeted radiopharmaceutical therapy in glioblastoma patients. Participants in the trial are patients with newly diagnosed verified or suspected GBM. The trial design is informed from clinical studies with the ligand forming the backbone of uTRACE, demonstrating that almost all GBM patients (94%), express uPAR on the tumour.

About the uPAR theranostic platform

Curasight’s uPAR theranostic platform combines two key technologies – uTRACE and uTREAT both targeting the uPAR receptor. uTRACE is designed to deliver sensitive imaging for diagnosis, while uTREAT offers a targeted radiopharmaceutical solution. Together, they form an integrated approach to improving the diagnosis and treatment of cancers that express uPAR. Curasight’s ambition is to develop both uTRACE and uTREAT to improve diagnosis and treatment of uPAR-expressing cancers.

About high grade glioma

Treatment of glioblastoma and other high-grade gliomas (WHO grades 3 or 4) presents a significant unmet medical need, necessitating innovative and effective treatments. A total of approx. 65,000 patients are diagnosed with primary brain tumors and more than 30,000 patients are diagnosed annually with the most aggressive form, glioblastoma, in the US and EU. Approximately 10 % of the patients are children. The prognosis for individuals with glioblastoma is very poor as approximately 50% of the patients die within 14 months and after five years from diagnosis only 5% are still alive. External beam radiation is a cornerstone in the therapy of brain cancers. uTREAT could potentially replace or reduce the use of external beam radiation and thereby lower side effects to the healthy brain due to more specific tumor tissue targeting.

(Press release, Curasight, NOV 26, 2025, View Source [SID1234660982])

On November 26, 2025 Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, reported that Noah Berkowitz, M.D., Ph.D., Chief Medical Officer, and Andrew Saik, Chief Financial Officer, will participate in a fireside chat at the Piper Sandler 37th Annual Healthcare Conference on Thursday, December 4 at 11:00 a.m. ET in New York.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live audio webcast of the presentation will be available here and on the Events and Presentations section of the Company’s website.

(Press release, Arvinas, NOV 26, 2025, View Source [SID1234660967])